Vets Synergetic Group LLC

Vets Synergetic Group LLC, an SBA 8(a) Joint Venture and minority-owned, small disadvantaged business based in Leesburg, Virginia, delivers scientific research support, regulatory compliance services, and technical staffing to the Food and Drug Administration as a prime contractor, competing predominantly under 8(a) set-asides (roughly 75% of recent awards carry 8(a) designations, split between Competitive 8(a) and 8(a) Sole Source).

Vets Synergetic Group LLC is a Subchapter S Corporation structured as a limited liability company and operates as a child entity of parent company Nitya, LLC, also a Subcontinent Asian (Asian-Indian) American-owned 8(a) certified small disadvantaged business. The vendor's capability portfolio centers on scientific research support across FDA regulatory domains—toxicology research, food safety assessment, pharmaceutical quality evaluation, computational toxicology, method development and validation, microbiological and chemical analysis, and specialized staffing augmentation through research scientists, data scientists, microbiologists, project managers, and quality assurance specialists. Representative work includes a $99.88 million single-award Indefinite Delivery Contract with FDA awarded June 4, 2024, valued at $99.88 million through June 9, 2028, which anchors the vendor's federal footprint; a $18.7 million delivery order for program management and interdisciplinary scientific support to the Office of Generic Drugs (awarded August 5, 2024); a $6.3 million task order for multiple research scientists supporting the Center for Drug Evaluation and Research, Office of Biotechnology Products (August 26, 2024); a $5.25 million delivery order for Scientist I and Researcher II positions supporting FDA's diverse regulatory domains (September 14, 2025); and a $5.37 million definitive contract for business process integration and solution architecture (April 29, 2024, 8(a) sole-source). The vendor also holds a Federal Supply Schedule contract with GSA awarded March 1, 2024, ceiling $475 thousand, covering 37 labor categories spanning Information Technology Professional Services and Cloud Computing, with hourly rates from $47.69 to $159.03 (no security clearances offered).

Customer concentration is extreme: FDA accounts for 87 of 90 awards (100% of combined potential value at $221.8 million). The Office of the Chief Financial Officer placed one $3.7 million delivery order for project management and financial operations support (January 5, 2026, 8(a) sole-source under GSA Schedule). GSA Federal Acquisition Service and the Centers for Medicare and Medicaid Services represent remaining orders of minor value. The vendor's award trajectory shows sharp acceleration—one award in 2017, then 23 in 2024, 52 in 2025, and 14 through mid-2026—reflecting rapid scaling under the parent FDA IDIQ. The recompete cliff is material: 40 awards (combined potential value $74.7 million) complete within the next twenty-four months.

The parent FDA Scientific Support IDIQ (contract 75F40124D00020) dominates the vehicle landscape, hosting 79 task orders worth $108.8 million combined potential value. The GSA Multiple Award Schedule accounts for 5 task orders worth $9.1 million combined potential value. Individual delivery order values range from approximately $40 thousand to over $18.7 million, structured as labor-hour, time-and-materials, or firm fixed-price arrangements depending on statement of work requirements.

Service Contract Inventory reporting shows $1.5 million in invoiced federal service revenue across FY2024, corresponding to 5.8 FTEs and 10 SCI-reportable prime contracts (the vendor carries zero sub-engagement across reported records). Government-paid hourly rates on SCI-reportable contracts run a median of approximately $115.97/hr, with the 10th percentile at $95.19/hr and the 90th percentile at $131.22/hr—positioning the vendor in the mid-market for scientific and technical labor. SCI data is a narrow slice of the vendor's federal services activity and does not reflect total enterprise revenue; the vendor's cumulative potential value across all 88 prime awards ($225.9 million) and obligated dollars to date ($71.7 million) indicate substantially larger federal services delivery than SCI alone captures.

The vendor operates primarily as a prime contractor (88 of 90 awards), with only two named sub-awards (Industrial Economics Inc. and Chickasaw Aerospace LLC on FDA Adverse Event systems modernization work). The vendor self-performs across its prime service contracts with no reported subcontractor hours in SCI-captured records, indicating a build-your-own-team model rather than a sub-heavy orchestration strategy. The 8(a) Joint Venture designation and minority-owned certification remain core to the vendor's competitive posture; the 8(a) certification expires August 30, 2026, creating a material recompete exposure cliff as that date approaches. Vets Synergetic Group LLC has no named GSA Schedule experience beyond the March 2024 vehicle; federal teaming is minimal, and the vendor operates as a direct-delivery prime focused on FDA scientific and technical staffing augmentation across multiple centers and offices.

VETS Synergetic Group, LLC (VSG) is a wholly owned subsidiary of Cognizance Technologies LLC. (CT), a HUBZone-certified and a woman-owned business (WOSB), is a fast-growing Small Business (SB), focused primarily in the Health IT space with a combined industry experience of over 100 person years. CT is committed to supporting it's client's mission with special emphasis on the full Data spectrum and digital information Over the last 5 years, CT has expanded its experience of managing, operating and delivering large scale IDIQ/BPA contracts, that are supporting concurrent multiple Task Orders (TOs), specifically centered around the areas of architecture, systems integration, data management, and O&M.